FreeGulliver LLC Boosts Stock Position in The Oncology Institute, Inc. (NASDAQ:TOI)

FreeGulliver LLC raised its stake in The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 219.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 600,747 shares of the company's stock after purchasing an additional 412,578 shares during the period. FreeGulliver LLC owned 0.80% of Oncology Institute worth $186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, HighTower Advisors LLC boosted its position in shares of Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company's stock worth $27,000 after purchasing an additional 53,382 shares in the last quarter. 36.86% of the stock is owned by institutional investors and hedge funds.

Oncology Institute Stock Up 3.8 %

NASDAQ:TOI traded up $0.04 during mid-day trading on Friday, hitting $1.00. 200,257 shares of the company's stock traded hands, compared to its average volume of 687,079. The company has a fifty day moving average of $0.78 and a 200 day moving average of $0.45. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $1.89. The company has a market capitalization of $75.27 million, a P/E ratio of -1.28 and a beta of 0.41.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.